Poxel S.A. (EPA:POXEL)
0.2810
-0.0380 (-11.91%)
Apr 2, 2026, 5:38 PM CET
Poxel Revenue
Poxel had revenue of 2.18M EUR in the half year ending June 30, 2025, with 128.59% growth. This brings the company's revenue in the last twelve months to 7.66M, up 249.95% year-over-year. In the year 2024, Poxel had annual revenue of 6.64M with 234.98% growth.
Revenue (ttm)
7.66M
Revenue Growth
+249.95%
P/S Ratio
1.97
Revenue / Employee
1.53M
Employees
5
Market Cap
15.10M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.64M | 4.66M | 234.98% |
| Dec 31, 2023 | 1.98M | 1.31M | 193.92% |
| Dec 31, 2022 | 674.00K | -12.72M | -94.97% |
| Dec 31, 2021 | 13.40M | 6.59M | 96.84% |
| Dec 31, 2020 | 6.81M | -19.75M | -74.37% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| genOway Société anonyme | 27.16M |
| Advicenne | 5.90M |
| Nicox | 3.32M |
| Aelis Farma | 2.33M |
| Plant Advanced Technologies | 2.22M |
| Oncodesign Precision Medicine Société anonyme | 1.74M |
| THX Pharma Société Anonyme | 876.13K |
| GenSight Biologics | 652.00K |
Poxel News
- 3 days ago - Poxel To Sell PXL770 To Scynexis For Up To $196 Mln; Shares Up - Nasdaq
- 9 days ago - Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan - Business Wire
- 6 weeks ago - Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position - Business Wire
- 2 months ago - Poxel Announces the Implementation of an Equity Line With IRIS Capital as Part of the Execution of the Recovery Plan - Business Wire
- 2 months ago - POXEL SA: The Commercial Court of Lyon Approves the Recovery Plan and Brings an End to the Judicial Reorganisation Proceedings - Business Wire
- 4 months ago - Poxel Publishes Its Financial Results for the First Half of 2025 - Business Wire
- 4 months ago - POXEL SA: Update on the Proposed Recovery Plan and Organisation of a Webinar - Business Wire
- 5 months ago - Poxel Reports Revenue for the Third Quarter 2025 - Business Wire